Haemonetics Corporation
HAE
Clasificación en acciones
#3262
Haemonetics Corporation is a healthcare enterprise dedicated to providing... Haemonetics Corporation is a healthcare enterprise dedicated to providing medical products and comprehensive solutions, structured into three main business areas: Plasma, Blood Center, and Hospital. In its Plasma segment, the company develops automated plasma collection systems, exemplified by the NexSys PCS and PCS2 devices, along with necessary disposables and intravenous solutions. It also offers integrated information technology platforms and the NexLynk DMS donor management system to help plasma customers efficiently manage their donors, operations, and supply chains. The Blood Center division provides advanced automated blood component and manual whole blood collection technologies. This includes MCS brand apheresis equipment for selectively collecting blood components, as well as disposable kits for whole blood collection and storage. Its software offerings feature the SafeTrace Tx blood bank information system and BloodTrack, a sophisticated suite of blood management software and hardware designed to enhance hospital blood bank functionalities and facilitate bedside transfusions. For the Hospital sector, Haemonetics offers hemostasis analyzer systems like TEG, ClotPro, and HAS, which deliver crucial assessments of a patient's overall clotting ability. The TEG Manager software links these analyzers throughout a facility, enabling clinicians to remotely access active and past test results to inform treatment decisions. Additionally, the Cell Saver Elite+ system supports autologous blood recovery across a wide range of surgical procedures, including cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological operations. The company distributes its products and solutions through its own direct sales teams, independent distributors, and sales representatives. Haemonetics Corporation was established in 1971 and is based in Boston, Massachusetts.
Precio por acción
$118.79
Capitalización bursátil
$5.40B
Cambio (1 día)
0.24%
Cambio (1 año)
134.25%
País
US
Comercio Haemonetics Corporation (HAE)
Categoría
Healthcare
Ratio P/E de Haemonetics Corporation (HAE)
Ratio P/E al October 2026 TTM: 58.79
Según los últimos informes financieros y el precio de las acciones de Haemonetics Corporation, el P/E actual (TTM) de la empresa es 58.79. Al final de 2024, la empresa tenía un P/E de 36.57.
Historial del ratio P/E de Haemonetics Corporation desde 2000 hasta 2026
Relación P/E al final de cada año
| Año | Ratio P/E | Cambiar |
|---|---|---|
| 2026 (TTM) | 58.79 | 209.92% |
| 2025 | 18.97 | -48.14% |
| 2024 | 36.57 | 0.43% |
| 2023 | 36.41 | -51.54% |
| 2022 | 75.14 | 5.15% |
| 2021 | 71.46 | 6.87% |
| 2020 | 66.87 | -18.39% |
| 2019 | 81.94 | -3.25% |
| 2018 | 84.69 | -206.46% |
| 2017 | -79.55 | 146.27% |
| 2016 | -32.30 | -123.96% |
| 2015 | 134.83 | 185.97% |
| 2014 | 47.15 | -14.48% |
| 2013 | 55.13 | 108.66% |
| 2012 | 26.42 | 26.60% |
| 2011 | 20.87 | -15.24% |
| 2010 | 24.62 | 5.04% |
| 2009 | 23.44 | -19.61% |
| 2008 | 29.16 | 14.54% |
| 2007 | 25.46 | 30.83% |
| 2006 | 19.46 | -27.03% |
| 2005 | 26.67 | 2.01% |
| 2004 | 26.14 | 34.39% |
| 2003 | 19.45 | -29.80% |
| 2002 | 27.71 | -76.06% |
| 2001 | 115.73 | 274.57% |
| 2000 | 30.90 | 0.00% |
Relación P/E para empresas similares o competidores
| Empresa | P/E Ratio | Diferencia del P/E Ratio | País |
|---|---|---|---|
| 33.11 | -43.68% |
US
|
|
| 21.39 | -63.62% |
IE
|
|
| 28.94 | -50.77% |
US
|
|
| 17.34 | -70.51% |
US
|
|
| - | - |
DE
|
¿Cómo leer un P/E ratio?
El ratio Precio/Beneficio (P/E Ratio) mide la relación entre el precio de las acciones de una empresa y sus beneficios por acción.
Un P/E bajo pero positivo indica una empresa con altos beneficios en relación a su valoración actual y que podría estar infravalorada. Una empresa con un P/E negativo alto (cerca de 0) indica fuertes pérdidas en comparación con su valoración.
Las empresas con un P/E superior a 30 o negativo suelen considerarse "acciones de crecimiento", lo que significa que los inversores esperan que crezca o se vuelva rentable en el futuro.
Las empresas con un P/E positivo inferior a 10 suelen considerarse "acciones de valor", lo que significa que ya son muy rentables y no se espera un fuerte crecimiento.